drugset
drugset / Trial / NCT00406276

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT00406276 ↗

Phase 1/2 Terminated 28 enrolled Emory University
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.

Timeline

Start
2006-11
Primary completion
2010-12
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 5 mg —
Background Docetaxel Small molecule — —

Indications

lung cancer